Rule 497(d)
FT 415
Bandwidth Select Portfolio, Series 3
e-Infrastructure Select Portfolio, Series 2
Genomics and Proteomics Select Portfolio Series
Global Technology Select Portfolio Series
Software Innovations 2000 Select Portfolio, Series 2
World Wide Wireless Select Portfolio, Series 2
Bandwidth Portfolio, Series 3
e-Infrastructure Portfolio, Series 2
Genomics and Proteomics Portfolio Series
Global Technology Portfolio Series
Software Innovations 2000 Portfolio, Series 3
World Wide Wireless Portfolio, Series 2
Supplement to the Prospectus dated March 3, 2000
Notwithstanding anything to the contrary in the Prospectus, Unit holders who
acquire Units of Genomics and Proteomics Select Portfolio Series, Genomics and
Proteomics Portfolio Series or Software Innovations 2000 Portfolio, Series 3
which, as a result of a reduction in the aggregate underlying value of the
Securities, are not subject to an initial sales charge will be subject to the
maximum remaining deferred sales charge (initially $.225 per Unit for the
Genomics and Proteomics Select Portfolio Series or $.35 per Unit for the
Genomics and Proteomics Portfolio Series or the Software Innovations 2000
Portfolio, Series 3). In such case the maximum sales charge may exceed 3.25%
of the Public Offering Price for Genomics and Proteomics Select Portfolio
Series or 4.5% of the Public Offering Price per Unit for Genomics and Proteomics
Portfolio Series and Software Innovations 2000 Portfolio, Series 3, but in no
event will the maximum sales charge exceed 3.75% of the Public Offering Price
per Unit for Genomics and Proteomics Select Portfolio Series or 5.50% of the
Public Offering Price per Unit for Genomics and Proteomics Portfolio Series or
Software Innovations 2000 Portfolio, Series 3.
April 3, 2000
